{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:28:07Z","timestamp":1767972487401,"version":"3.49.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.jaip.2013.07.004","type":"journal-article","created":{"date-parts":[[2013,9,7]],"date-time":"2013-09-07T23:16:34Z","timestamp":1378595794000},"page":"687-688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome"],"prefix":"10.1016","volume":"1","author":[{"given":"Elizabeth Nicole","family":"da Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina Louise","family":"Randall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2013.07.004_bib1","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1365-2222.2011.03788.x","article-title":"Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines","volume":"41","author":"Krishna","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2013.07.004_bib2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2013.07.004_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0091-6749(97)81058-5","article-title":"Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis","volume":"99","author":"Oude Elberink","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2013.07.004_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaci.2010.04.025","article-title":"Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: The importance of baseline serum tryptase","volume":"126","author":"Rueff","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2013.07.004_bib5","first-page":"225","article-title":"Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab","volume":"19","author":"Galera","year":"2009","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2013.07.004_bib6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1398-9995.2007.01388.x","article-title":"Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab","volume":"62","author":"Schulze","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2013.07.004_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","article-title":"High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis","volume":"63","author":"Kontou-Fili","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2013.07.004_bib8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1398-9995.2009.02045.x","article-title":"Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis","volume":"64","author":"Kontou-Fili","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2013.07.004_bib9","first-page":"225","article-title":"Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy","volume":"18","author":"Soriano Gomis","year":"2008","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2013.07.004_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fc\u03b5RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2013.07.004_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.anai.2010.04.011","article-title":"Omalizumab monotherapy for bee sting and unprovoked \u201canaphylaxis\u201d in a patient with systemic mastocytosis and undetectable specific IgE","volume":"104","author":"Kontou-Fili","year":"2010","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219813002985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219813002985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:07:00Z","timestamp":1761973620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219813002985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S2213219813002985"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2013.07.004","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2013.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}